Surgical exploration with non-resection in the setting of resectable, borderline and locally advanced pancreatic cancer

Pancreatic cancer has an overall dismal prognosis compared to most other malignancies.In general,only about 15%-20%of patients are deemed upfront resectable at time of diagnosis,with a similar proportion presenting with either borderline or locally advanced disease[1].Novel and more effective treatment regimens including FOLFIRINOX have made yet more patients become resectable,with up to 60%reported in some centers[2].